

DAFTAR PUSTAKA

- Agustinus A., Uloaku Ogbuagu U., Ogbuagu E., Oloruntoba A, Agunbiade A.P., Airaodion E.O., Mokelu I.P, Ekeh S.C. 2019. Mechanisms for Controlling the Synthesis of Lipids Review. International Journal of Research Volume 06 Issue 2 <https://pen2print.org/index.php/ijr/>
- American Diabetes Association. (2022). Standards of Medical Care in Diabetes—2022 Abridged for Primary Care Providers. VOLUME 40, NO. 1. <https://doi.org/10.2337/cd22-as01>
- Artha, I.M., Bhargah A., Dharmawan N.K., Pande U.W., Triyana K.A., Mahariski P.A., Yuwono J., Bhargah V., Prabawa I.P., Putra I.B., Manuaba, Rina I.K. (2019). High Level Of Individual Lipid Profile And Lipid Ratio As A Predictive Marker Of Poor Glycemic Control In Type-2 Diabetes Mellitus. *Vascular Health and Risk Management* Vol 15: 49–157
- Asih R.S., Alifiar I., Purwandy Y. Pengaruh Kronofarmakologi Terhadap Kadar Kolesterol Total Dan Trigliserida Dalam Darah Pasien Pengguna Obat Golongan Statin Dan Fibrat. *JFL* Vol 9 No. 2 , Desember 2020.
- Bore´na J. and Williams K. The central role of arterial retention of cholesterolrich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Volume 27 : NO. 5
- Decroli E. 2019. *Diabetes Melitus Tipe 2* . Pusat Penerbitan Bagian Ilmu Penyakit Dalam : Padang. ISBN No.978-602-1332-25-2
- Dong H., Ni W., Bai Y., Yuan X., Zhang Y. (2022). Cross-Sectional And Longitudinal Associations Of Apolipoprotein A1 And B With Glycosylated Hemoglobin In Chinese Adults. *Scientific Reports* 12:2751
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood

Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.

Fatimah R.N. Diabetes Melitus Tipe 2. J Majority Volume 4 Nomor 5 Februari 2015

Gantala, S. R., Kummari, R., Tupurani, M. A., Galimudi, R. K., & Gundapaneni, K. K. (2018). Evaluation of Glycemic, Lipid, Immunoinflammatory and Oxidative Stress Markers in Various Clinical Stages of Type 2 Diabetic Nephropathy. J Metabolic Syndr 7: 237. doi: 10.4172/2167-0943.1000237 Page 2 of 7 J Metabolic Syndr, an open access journal 7 (1), 1000237.

German C. & Shapiro M. 2020. Assessing Atherosclerotic Cardiovascular Disease Risk with Advanced Lipid Testing: State of the Science. Division of Cardiovascular Disease, Center for Preventive Cardiology.

Gupta S., Chauhan N., Jain U. (2017). Laboratory diagnosis of hba1c: a review. J Nanomed Res. :5(4):11–12
<https://medcraveonline.com/JNMR/laboratory-diagnosis-of-hba1c-a-review.html>

Huff T., Boyd B, Jialal I. 2022. Physiology, Cholestrerol. Stat Pearls Publishing
<https://www.ncbi.nlm.nih.gov/books/NBK470561/#!po=90.3846>

Hussain S, Shareef U, Giriraja, Mohan L. Correlation between Glycosylated Haemoglobin and Serum Lipid Profile in Patients with Type 2 Diabetes Mellitus in A Rural Tertiary Care Hospital, Karnataka, India. IAR Journal of Medical Sciences. 2020;1(6):290–5.

Holtzman D.M. , Basak, Verghese, Yoon H., Kim J. 2012. Low-density Lipoprotein Receptor Represents an Apolipoprotein E-independent Pathway of A Uptake and Degradation by Astrocytes. THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 287, NO. 17

Jim E. 2013. Metabolisme Lipoprotein. Jurnal Biomedik (JBM), Volume 5, Nomor 3 hlm. 149-156

Jomard A. and Osto E. High Density Lipoproteins: Metabolism, Function, and Therapeutic Potential. Frontiers in Cardiovascular Medicine March 2020 Volume 7

Juda T., Zidan H., Issa A. (2016). Polymorphism of Aldose Reductase Gene and Susceptibility for Developing Diabetic Retinopathy among Type 2 Diabetes Mellitus Patients. Journal of Babylon University No.(5)/ Vol.(24)

<https://www.researchgate.net/publication/314095829>

Jung H., Hong S., Kim K.S. (2021) Comparison of apolipoprotein B/A1 ratio, TC/HDL-C, and lipoprotein (a) for predicting outcomes after PCI. PLoS ONE 16(7)

Katwal P C, Jirjees S, Htun Z, et al. (June 03, 2020) The Effect of Anemia and the Goal of Optimal HbA1c Control in Diabetes and Non-Diabetes. Cureus 12(6): e8431. DOI 10.7759/cureus.8431

Kaneva, AM., Potolitsyna, NN., Bojko, ER., Odland, JO. 2015. The Apolipoprotein B/Apolipoprotein A-I Ratio as a Potential Marker of Plasma Atherogenicity. Hindawi, 1-7.

Khan HA. Clinical significance of HbA1c as a marker of circulating lipids in male and female type 2 diabetic patients. Acta Diabetol 2007.

Kharroubi AT, Darwish HM. Diabetes mellitus: The epidemic of the century. World J Diabetes 2015; 6(6): 850-867 Available from: URL: <http://www.wjgnet.com/1948-9358/full/v6/i6/850.htm> DOI: <http://dx.doi.org/10.4239/wjd.v6.i6.850>

Kundi, H.; Korkmaz, A.; Balun, A.; Cicekcioglu, H.; Kiziltunc, E.; Gursel, K.; Cetin, M.; Ornek, E.; Ileri, M. Is In-Stent Restenosis After a Successful Coronary Stent Implantation Due to Stable Angina Associated With TG/HDL-C Ratio Angiology 2017, 68, 816–822. DOI: <https://doi.org/10.1177/0003319716689366>

- Listiyana A.D., Mardiana, Prameswari G.N. 2013. Obesitas sentral dan kadar kolesterol darah total. *Kemas* 9 (1) (2013) 37-43
<http://journal.unnes.ac.id/nju/index.php/kemas>
- Mahwal I., Untari E., Nurmainah. Perbandingan Statin Terhadap Kejadian Efek Samping Terkait Myalgia. *J. Sains Kes.* 2022. Vol 4. No 2.
- Martin S.S., Qasim A.N., Mehta N., Wolfe M., Terembula K. 2009. Apolipoprotein B but not LDL Cholesterol Is Associated With Coronary Artery Calcification in Type 2 Diabetic Whites: *DIABETES*, VOL. 58
- Mashabi, Y. 2019. Penilaian Rasio Apo B/Apo A1 pada Subjek Sindrom Metabolik dan Obesitas. Tesis. Medan: Program Magister Klinik-Spesialis Ilmu Patologi Klinik Fakultas Kedokteran Universitas Sumatera Utara.
- Megawati, Kurniawan L. B., Bahrin U. (2022). Hubungan Rasio APO-B/APO A-I dengan Index Massa Tubuh. *Jurnal Kesehatan* Volume 13, Nomor 1
<http://ejurnal.poltekkes-tjk.ac.id/index.php/JK>
- Millan J., Pinto X., Munoz A., Zuniga M., Rubies J., Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. *Vascular Health and Risk Management* 2009;5 757–765.
- Obed Huger Nainggolan O. H. & Wulanjani H. A. Hubungan Ratio Trigliserida/HDL-C dengan HbA1c pada Penderita Diabetes Melitus Tipe 2. *Medica Hospitalia* | Vol. 5, No. 1, Mei 2018
- Parveen, K., Siddiqui, W.A., Kausara, M.A., Kuddusa, M., & Syed Monowar, A.S. (2016). Diabetic nephropathy - a major macrovascular complication. *Int J Pharmaceuti Res Allied Sci.* 5, 132-58.
- PERKENI. 2019. Pengelolaan Dislipidemia Di Indonesia. PB PERKENI

- Pinakesty A., Aziza R. (2020). Hubungan Profil Lipid Dengan Progresivitas Diabetes Melitus Tipe 2. Fakultas Kedokteran, Universitas Muhammadiyah Surakarta. Volume 8 No.2
- Pushparaj J.L., & Kirubakaran S.S. 2014. HbA1c As A Predictor Of Lipid Profile In Type 2 Diabetic Patients. J of Evolution of Med and Dent Sci/ eISSN- 2278-4802 Vol. 3
- Putri S. R., Angraini D.I, Kurniawan. 2017. Korelasi Asupan Makan terhadap Kadar Trigliserida pada Mahasiswa Obesitas di Fakultas Kedokteran Universitas Lampung. J Agromed Unila Volume 4 Nomor 2
- Reed J., Bain S., Venkateswarlu, Kanamarlapudi. (2021). A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives. Medical School, Swansea University, Swansea. <https://doi.org/10.2147/DMSO.S319895>
- Rey & Barter. Regulation of High-Density Lipoprotein Metabolism. *CircRes*.2014;114:124142
- Ruihua, Yijunli, Wenyan, Zhen Wei, (2021). Apolipoprotein B/A1 Ratio Is Associated with Severity of Coronary Artery Stenosis in CAD Patients but Not in Non-CAD Patients Undergoing Percutaneous Coronary Intervention. *Disease Markers* Article ID 8959019, <https://doi.org/10.1155/2021/8959019>
- Sanllorente A., Lassale C., Soria M., Castaner O. Modification of High-Density Lipoprotein Functions by Diet and Other Lifestyle Changes: A Systematic Review of Randomized Controlled Trials. *J. Clin. Med.* 2021, 10, 5897
- S.C. Thambiah & L.C. Lai (2021) Diabetic dyslipidaemia. *Practical Laboratory Medicine* 26
- Siregar F., & Makmur T. 2020. Metabolisme Lipid Dalam Tubuh. *Jurnal Inovasi Kesehatan Masyarakat* Vol. 1 No. 2 <http://ejournal.delihusada.ac.id/index.php/JIKM>
- Sherwani S., Khan H., Ekhzaimy A. (2016). Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients. *Biomarker Insights* 2016:11

- Srilaning D., Rachmawati B., Asti H. (2016). Hubungan Antara HbA1c Dengan LDL-K dan Albuminuria pada Penderita DM dengan Riwayat Komplikasi Jantung Koroner. *Jurnal Biotek Medisiana Indonesia* . Vol.5.2
- Utomo A., R. Andira, Rahmah S., Amalia R. (2020). Faktor Risiko Diabetes Mellitus Tipe 2. *Jurnal Kajian dan Pengembangan Kesehatan Masyarakat* Vol. 01 No. 01 Hal. 44 – 52
<https://jurnal.umj.ac.id/index.php/AN-NUR>
- Wadhera R.K., Steen D.L., Khan I., Giugliano R.P., Foody J.M. 2015. A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on Q1 cardiovascular disease morbidity and mortality. *Journal of Clinical Lipidology*
<http://dx.doi.org/10.1016/j.jacl.2015.11.010>
- Wahab, Z., Novitasari, A., & W, N. F. (2017). Profil lipid sebagai kontrol glikemik pada pasien diabetes mellitus tipe II.
<http://digilib.unimus.ac.id>
- Walldius, G., Jungner, I. 2006. The Apo B/Apo A-1 ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy—a review of the evidence. *Journal of Intern Med*, 259: 493– 519.
- Walldius, G., Jungner, I., Holme, I., Aastveit, A. H., Kolar, W., Steiner, E. 2001. High apolipoprotein B, Low apolipoprotein A-I, and Improvement in the Prediction of Fatal Myocardial Infarction (AMORIS Study): a prospective study. *Lancet*, 358: 2026–33.
- Westman E.C. Type 2 Diabetes Mellitus: A Pathophysiologic Perspective. August (2021) Volume 8
- Widyatmojo H., Suromo L., Retroningrum D. (2018). Hubungan Hemoglobin Terглиkosilasi (Hba1c) Dengan Risiko Kardiovaskular Pada Pasien Diabetes Mellitus. *Media Medika Muda*: Volume 3, No. 2
- Wulandari, I. A. T., Herawati, S., & Wande, I. N. (2020). Gambaran Kadar Hba1c Pada Pasien Diabetes Melitus Tipe Ii Di Rsup Sanglah. *Jurnal Medika Udayana*, VOL. 9 NO.1
<https://ojs.unud.ac.id/index.php/eum>

- Yan, Z., Liu, Y., & Huang, H. (2012). Association of glycosylated hemoglobin level with lipid ratio and individual lipids in type 2 diabetic patients. *Journal of Tropical Medicine*. 469-471.
- Yudha N. S. D., Arsana P. M., Rusandi R. (2021). Perbandingan Profil Lipid pada Pasien Diabetes Melitus Tipe 2 dengan Kontrol Glikemik yang Terkendali dan Kontrol Glikemik yang Tidak Terkendali di RSUD Dr. Saiful Anwar Malang. *Jurnal Penyakit Dalam Indonesia* Vol. 8, No. 4
- Zheng S., Han T., Xu H., Zhou H., Ren X. (2017). Associations Of Apolipoprotein B/Apolipoprotein A-I Ratio With Pre-Diabetes And Diabetes Risks: A Cross-Sectional Study In Chinese Adults. . *BMJ Open* 2017;7:e014038. doi:10.1136/bmjopen-2016-014038

LAMPIRAN

Lampiran 1. Surat Izin Etik



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.



Contact Person: dr. Agussalim Bukhari., MMed, PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 164/UN4.6.4.5.31/ PP36/ 2023

Tanggal: 13 Maret 2023

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH23020101	No Sponsor Protokol	
Peneliti Utama	Irmawati	Sponsor	
Judul Peneliti	KORELASI HbA1c DENGAN RASIO KOLESTEROL TOTAL/HDL, LDL/HDL, TG/HDL DAN RASIO APOLIPOPROTEIN B/APOLIPOPROTEIN A-1 SERUM PADA PENDERITA DIABETES MELITUS TIPE 2		
No Versi Protokol	2	Tanggal Versi	8 Maret 2023
No Versi PSP	2	Tanggal Versi	8 Maret 2023
Tempat Penelitian	RS Universitas Hasanuddin dan RS Labuang Baji Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 13 Maret 2023 sampai 13 Maret 2024	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 2. Surat Izin Penelitian



PEMERINTAH PROVINSI SULAWESI SELATAN
RUMAH SAKIT UMUM DAERAH LABUANG BAJI
JL. Dr. RATULANGI NO. 81 Telp. 873482 - 872120 - 872836 – 874684 Fax : 0411-830454
E-mail: rumahsakitlabuangbaji@yahoo.co.id
MAKASSAR

REKOMENDASI

Nomor: 800.2.2.6/ 130 /LB-02/I/2023

Berdasarkan Surat dari Universitas Hasanuddin Makassar Nomor : 12618/UN4.20.1/PT.01.04/2023 Tanggal 28 April 2023 Perihal : Permintaan Izin Pengambilan Data Awal, dengan ini di sampaikan bahwa yang tersebut namanya di bawah ini :

Nama : Irmawati
NIM : P062212023
Program Studi : Ilmu Biomedik
Pekerjaan : Mahasiswa S2 Unhas
Alamat : Jl. Perintis Kemerdekaan Km 10 Makassar

Diberikan rekomendasi untuk :

Melakukan Pengambilan Data Awal/ Penelitian dalam rangka penyusunan Karya Tulis Ilmiah/Skripsi/Tesis Pada Di Rumah Sakit Umum Daerah Labuang Baji Dengan Judul **"KORELASI HbA1c DENGAN RASIO KOLESTEROL TOTAL/HDL, LDL/HDL, TG/HDL DAN RASIO APOLIPROTEIN B/ APOLIPROTEIN A-1 SERUM PADA PENDERITA DIABETES MILITUS TIPE 2"**

Demikian rekomendasi ini dibuat untuk dipergunakan sebagaimana mestinya.

Makassar, 8 Mei 2023

An. Wadir, Umum, SDM dan Pendidikan
Kepala Bagian Diklat



Lampiran 3. Data Primer

KODE SPESIMEN	JENIS KELAMIN	UMUR	HBA1C	APO B	APO A	RASIO APO B/APO A	CHOL	LDL	HDL	TG	RASIO LIPID		
											CHOL/HDL	LDL/HDL	TG/HDL
14	P	55	10,3	92,5	79,1	1,17	242,41	150,4	30,84	101,34	7,86	4,88	3,29
19	L	60	7,6	130,5	88	1,48	258,96	114,99	23,98	242,62	10,80	4,80	10,12
21	P	56	10	83	77,6	1,07	236,73	153	44,26	220,7	5,35	3,46	4,99
22	P	61	8,3	147,7	67,3	2,19	267,63	192	54	192,78	4,96	3,56	3,57
23	L	53	9,4	207,3	125,2	1,66	645,77	219,65	22,85	213,61	28,26	9,61	9,35
24	P	64	9	304,5	93,7	3,25	239	454	16,51	58	14,48	27,50	3,51
26	L	69	8	82,7	142,5	0,58	253,39	54,37	17,93	477,23	14,13	3,03	26,62
27	P	56	8,1	134,7	132,8	1,01	255,21	156,52	25,05	114,6	10,19	6,25	4,57
28	P	55	10	113,5	117,9	0,96	239,06	138,4	23,68	142,81	10,10	5,84	6,03
32	P	62	11,6	141,2	160,5	0,88	242,02	142,82	23,14	150,32	10,46	6,17	6,50
33	P	50	11,1	191	108,2	1,77	314,11	152,77	16,65	275,6	18,87	9,18	16,55
34	P	53	11,1	90,4	148,3	0,61	164,86	69,14	24,75	189,76	6,66	2,79	7,67
35	L	57	10,4	85,7	156,3	0,55	175,06	64,45	25,71	179,47	6,81	2,51	6,98
39	P	63	8,2	90,9	80,8	1,13	197,65	110,17	48,47	114,32	4,08	2,27	2,36
40	P	49	7,9	97,7	134,6	0,73	151,96	69,93	22,13	176,47	6,87	3,16	7,97
41	P	47	7,6	97,1	182,8	0,53	235,51	105,49	46,99	186,15	5,01	2,24	3,96
42	P	63	10	89,3	99,5	0,90	195,84	112,02	23,57	100,19	8,31	4,75	4,25
43	P	58	10,1	120	153,2	0,78	216,61	128,59	25,2	118,81	8,60	5,10	4,71
44	P	59	7,4	168,8	79,8	2,12	247	146	73	117	3,38	2,00	1,60
45	L	65	7,7	116,2	91,7	1,27	264	95	17,34	359	15,22	5,48	20,70
46	P	43	11,5	174,6	149,2	1,17	261,8	181	20,15	238,96	12,99	8,98	11,86
47	L	60	8,3	92,1	130,2	0,71	128,75	67,74	24,96	143,1	5,16	2,71	5,73
48	L	63	15,9	213,1	196	1,09	398,16	260,78	38,37	229,48	10,38	6,80	5,98
49	L	62	9,9	62,5	131	0,48	213,51	123,71	39,86	100,57	5,36	3,10	2,52
56	P	61	14,4	130,5	136,7	0,95	220,3	127,77	22,6	129,62	9,75	5,65	5,74
58	L	70	7,7	47,3	155,1	0,30	119,21	35,7	31,99	152,46	3,73	1,12	4,77
61	P	63	10,8	110,5	100,1	1,10	199,8	169	45	136	4,44	3,76	3,02
62	L	54	9	139,8	140,4	1,00	204,19	97,42	18,09	188,21	11,29	5,39	10,40
65	L	56	13,6	135,5	125,4	1,08	336,27	203,37	41,04	180,45	8,19	4,96	4,40
66	P	39	7	98,9	89,1	1,11	145,41	89,9	21,64	74,3	6,72	4,15	3,43
69	P	45	14,6	100,7	22,8	4,42	229,27	96,12	38,28	400	5,99	2,51	10,45
76	L	61	7,6	141,4	125	1,13	188,67	120,93	29,67	129,89	6,36	4,08	4,38
78	P	73	7,2	101,7	24,9	4,08	261,93	129,12	22,94	217,12	11,42	5,63	9,46
80	P	53	8,8	135,2	138,7	0,97	195,16	86,04	28,18	240,89	6,93	3,05	8,55
81	P	52	7	112,2	140,5	0,80	182,82	105,84	26,65	140,16	6,86	3,97	5,26
82	L	67	9,7	84,2	208,8	0,40	176,68	83,22	51,41	119,44	3,44	1,62	2,32
84	L	61	10,1	118,8	135,4	0,88	207,22	136,27	39,72	135,69	5,22	3,43	3,42
86	L	47	9,7	119,4	122,6	0,97	203,83	101,66	21,2	200,87	9,61	4,80	9,48
87	P	64	11,5	153,6	169,3	0,91	242,96	129,7	33,8	225,24	7,19	3,84	6,66
88	P	46	9,6	106,1	139,3	0,76	141,81	76,79	34,39	77,21	4,12	2,23	2,25
89	L	84	9,2	78,8	160	0,49	148,12	79,49	36,88	101,09	4,02	2,16	2,74
90	P	65	13,8	209,5	136	1,54	249,42	158,03	44,97	113,72	5,55	3,51	2,53
94	L	57	7,1	101,3	162,9	0,62	178,53	96,61	38,54	105,82	4,63	2,51	2,75
95	P	63	9,4	119	206,2	0,58	233,2	137,61	55,54	199,32	4,20	2,48	3,59
96	L	53	7,2	152,8	66,9	2,28	312,79	203,65	24,86	178,44	12,58	8,19	7,18
97	P	58	7,2	88,9	187,8	0,47	170,27	72,26	42,93	163,84	3,97	1,68	3,82
99	L	39	8,5	180,1	140,4	1,28	216,57	104,99	31,72	200,87	6,83	3,31	6,33
101	P	63	12,4	121,8	109,9	1,11	295,86	127,97	33,35	291,15	8,87	3,84	8,73

KODE SPESIMEN	JENIS KELAMIN	UMUR	HBA1C	APO B	APO A	RASIO APO B/APO A	CHOL	LDL	HDL	TG	RASIO LIPID		
											CHOL/HDL	LDL/HDL	TG/HDL
25	L	68	6,6	32,5	134	0,24	117,53	36,83	37,78	154,84	3,11	0,97	4,10
50	P	56	6,3	85,4	118,6	0,72	176,67	53,1	24,5	218,67	7,21	2,17	8,93
52	P	52	5,8	121,9	187,6	0,65	137,37	56,4	27,74	88,29	4,95	2,03	3,18
54	L	44	6,6	86,8	126,9	0,68	130,19	52,8	21,89	141,71	5,95	2,41	6,47
71	L	63	6,2	66	99	0,67	116,26	69,21	26,65	83,06	4,36	2,60	3,12
79	L	42	6,5	75,6	111,3	0,68	153,93	71,09	26,74	93,38	5,76	2,66	3,49
83	P	63	6,2	88,1	144,5	0,61	157,18	73,88	35,16	147,07	4,47	2,10	4,18
91	P	67	6,9	106,8	161,9	0,66	173,11	73,48	49,45	122,21	3,50	1,49	2,47
92	L	61	6,7	90	150	0,60	174,52	90,84	30,84	122,79	5,66	2,95	3,98
93	P	72	6	99,1	99,4	1,00	175,91	120,47	19,7	99,48	8,93	6,12	5,05

Lampiran 4. Analisis Data

Karakteristik Umum Subjek Penelitian

Jenis Kelamin

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Laki-laki	26	43.3	43.3	43.3
	Perempuan	34	56.7	56.7	100.0
	Total	60	100.0	100.0	

Umur

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	36-45 tahun	6	10.0	10.0	10.0
	46-55 tahun	14	23.3	23.3	33.3
	56-65 tahun	32	53.3	53.3	86.7
	>65 tahun	8	13.3	13.3	100.0
	Total	60	100.0	100.0	

Statistics

		HBA1	APO	APO	APO					CHOL/	LDL/	TG/H
		C	B	A	B/APO	CHOL	LDL	HDL	TG	HDL	HDL	DL
N	Valid	60	60	60	60	60	60	60	60	60	60	60
	Missing	0	0	0	0	0	0	0	0	0	0	0
Mean		8.9783	118.0733	128.6967	1.0858	215.5000	118.6087	31.6313	168.1538	7.7015	4.2790	6.1415
Std. Error of Mean		.30550	5.85929	5.08581	.10199	10.39661	8.27657	1.48175	10.04599	.55686	.46873	.56656
Median		8.4000	108.6500	133.4000	.9050	204.0100	108.0050	27.8300	148.6950	6.7650	3.4450	4.7400
Mode		7.20 ^a	130.50	140.40	.58 ^a	116.26 ^a	35.70 ^a	26.65 ^a	200.87	3.11 ^a	2.51	1.60 ^a
Std. Deviation		2.36637	45.38583	39.39453	.78998	80.53180	64.11006	11.47760	77.81591	4.31340	3.63079	4.38853
Variance		5.600	2059.874	1551.929	.624	6485.370	4110.099	131.735	6055.317	18.605	13.183	19.259
Range		10.10	272.00	186.00	4.18	529.51	418.30	56.49	419.23	25.15	26.53	25.02
Minimum		5.80	32.50	22.80	.24	116.26	35.70	16.51	58.00	3.11	.97	1.60
Maximum		15.90	304.50	208.80	4.42	645.77	454.00	73.00	477.23	28.26	27.50	26.62
Sum		538.70	7084.40	7721.80	65.15	12930.00	7116.52	1897.88	10089.23	462.09	256.74	368.49

a. Multiple modes exist. The smallest value is shown

B. Uji Normalitas
- Uji Normalitas (Keseluruhan)

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
HBA1C	.113	60	.055	.924	60	.001
CHOL/HDL	.179	60	.000	.799	60	.000
LDL/HDL	.194	60	.000	.578	60	.000
TG/HDL	.171	60	.000	.743	60	.000
APO B/APO A	.258	60	.000	.703	60	.000

a. Lilliefors Significance Correction

C. Uji Perbandingan

Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
CHOL/HDL	60	7.7015	4.31340	3.11	28.26
LDL/HDL	60	4.2790	3.63079	.97	27.50
TG/HDL	60	6.1415	4.38853	1.60	26.62
APO B/APO A	60	1.0858	.78998	.24	4.42
Kelompok	60	1.2000	.40338	1.00	2.00

Mann-Whitney Test

Ranks

	Kelompok	N	Mean Rank	Sum of Ranks
CHOL/HDL	Tidak Terkontrol ($\geq 7\%$)	48	32.85	1577.00
	Terkontrol ($< 7\%$)	12	21.08	253.00
	Total	60		
LDL/HDL	Tidak Terkontrol ($\geq 7\%$)	48	33.63	1614.00
	Terkontrol ($< 7\%$)	12	18.00	216.00
	Total	60		
TG/HDL	Tidak Terkontrol ($\geq 7\%$)	48	31.81	1527.00
	Terkontrol ($< 7\%$)	12	25.25	303.00
	Total	60		
APO B/APO A	Tidak Terkontrol ($\geq 7\%$)	48	33.78	1621.50
	Terkontrol ($< 7\%$)	12	17.38	208.50
	Total	60		

Test Statistics^a

	CHOL/HDL	LDL/HDL	TG/HDL	APO B/APO A
Mann-Whitney U	175.000	138.000	225.000	130.500
Wilcoxon W	253.000	216.000	303.000	208.500
Z	-2.088	-2.772	-1.164	-2.911
Asymp. Sig. (2-tailed)	.037	.006	.244	.004

a. Grouping Variable: Kelompok

D. Uji Korelasi

Correlations

			HBA1C	CHOL/HDL
Spearman's rho	HBA1C	Correlation Coefficient	1.000	.298*
		Sig. (2-tailed)	.	.021
		N	60	60
	CHOL/HDL	Correlation Coefficient	.298*	1.000
		Sig. (2-tailed)	.021	.
		N	60	60

*. Correlation is significant at the 0.05 level (2-tailed).

Correlations

			HBA1C	LDL/HDL
Spearman's rho	HBA1C	Correlation Coefficient	1.000	.393**
		Sig. (2-tailed)	.	.002
		N	60	60
	LDL/HDL	Correlation Coefficient	.393**	1.000
		Sig. (2-tailed)	.002	.
		N	60	60

** Correlation is significant at the 0.01 level (2-tailed).

Correlations

			HBA1C	TG/HDL
Spearman's rho	HBA1C	Correlation Coefficient	1.000	.181
		Sig. (2-tailed)	.	.165
		N	60	60
	TG/HDL	Correlation Coefficient	.181	1.000
		Sig. (2-tailed)	.165	.
		N	60	60

Correlations

			HBA1C	APO B/APO A
Spearman's rho	HBA1C	Correlation Coefficient	1.000	.308*
		Sig. (2-tailed)	.	.017
		N	60	60
	APO B/APO A	Correlation Coefficient	.308*	1.000
		Sig. (2-tailed)	.017	.
		N	60	60


*. Correlation is significant at the 0.05 level (2-tailed).

E. PERHITUNGAN NILAI CUT OFF

Case Processing Summary

Kelompok	Valid N (listwise)
Positive ^a	48
Negative	12

Larger values of the test result variable(s) indicate stronger evidence for a positive actual state.
a. The positive actual state is Tidak Terkontrol ($\geq 7\%$).



Diagonal segments are produced by ties.

Area Under the Curve

Test Result Variable(s)	Area	Std. Error ^a	Asymptotic Sig. ^b	Asymptotic 95% Confidence Interval Lower Bound	Asymptotic 95% Confidence Interval Upper Bound
APO B/APO A	.773	.060	.004	.655	.892
CHOL/HDL	.696	.074	.037	.551	.842
LDL/HDL	.760	.079	.006	.606	.914
TG/HDL	.609	.078	.244	.457	.762

The test result variable(s): APO B/APO A has at least one tie between the positive actual state group and the negative actual state group. Statistics may be biased.

a. Under the nonparametric assumption

b. Null hypothesis: true area = 0.5

Coordinates of the Curve

Test Result Variable(s)	Positive if Greater Than or Equal To ^a	Sensitivity	1 - Specificity
APO B/APO A	-.7600	1.000	1.000
	.2700	1.000	.917
	.3500	.979	.917
	.4350	.958	.917
	.4750	.938	.917
	.4850	.917	.917
	.5100	.896	.917

.5400	.875	.917
.5550	.854	.917
.5700	.854	.833
.5900	.813	.833
.6050	.813	.750
.6150	.792	.667
.6350	.771	.667
.6550	.771	.583
.6650	.771	.500
.6750	.771	.417
.6950	.771	.250
.7150	.750	.250
.7250	.750	.167
.7450	.729	.167
.7700	.708	.083
.7900	.688	.083
.8400	.667	.083
.8900	.625	.083
.9050	.604	.083
.9300	.583	.083
.9550	.563	.083
.9650	.542	.083
.9850	.500	.083
1.0050	.479	.000
1.0400	.458	.000
1.0750	.438	.000
1.0850	.417	.000
1.0950	.396	.000
1.1050	.375	.000
1.1200	.333	.000
1.1500	.292	.000
1.2200	.250	.000
1.2750	.229	.000
1.3800	.208	.000
1.5100	.188	.000
1.6000	.167	.000
1.7150	.146	.000

	1.9450	.125	.000
	2.1550	.104	.000
	2.2350	.083	.000
	2.7650	.063	.000
	3.6650	.042	.000
	4.2500	.021	.000
	5.4200	.000	.000
CHOL/HDL	2.1100	1.000	1.000
	3.2450	1.000	.917
	3.4100	.979	.917
	3.4700	.958	.917
	3.6150	.958	.833
	3.8500	.938	.833
	3.9950	.917	.833
	4.0500	.896	.833
	4.1000	.875	.833
	4.1600	.854	.833
	4.2800	.833	.833
	4.4000	.833	.750
	4.4550	.813	.750
	4.5500	.813	.667
	4.7400	.792	.667
	4.9000	.792	.583
	4.9550	.792	.500
	4.9850	.771	.500
	5.0850	.750	.500
	5.1900	.729	.500
	5.2850	.708	.500
	5.3550	.688	.500
	5.4550	.667	.500
	5.6050	.646	.500
	5.7100	.646	.417
	5.8550	.646	.333
	5.9700	.646	.250
	6.1750	.625	.250
	6.5100	.604	.250
	6.6900	.583	.250

	6.7650	.563	.250
	6.8200	.542	.250
	6.8450	.521	.250
	6.8650	.500	.250
	6.9000	.479	.250
	7.0350	.458	.250
	7.1650	.458	.167
	7.2000	.438	.167
	7.5350	.438	.083
	8.0250	.417	.083
	8.2500	.396	.083
	8.4550	.375	.083
	8.7350	.354	.083
	8.9000	.333	.083
	9.2700	.333	.000
	9.6800	.313	.000
	9.9250	.292	.000
	10.1450	.271	.000
	10.2850	.250	.000
	10.4200	.229	.000
	10.6300	.208	.000
	11.0450	.188	.000
	11.3550	.167	.000
	12.0000	.146	.000
	12.7850	.125	.000
	13.5600	.104	.000
	14.3050	.083	.000
	14.8500	.063	.000
	17.0450	.042	.000
	23.5650	.021	.000
	29.2600	.000	.000
LDL/HDL	-.0300	1.000	1.000
	1.0450	1.000	.917
	1.3050	.979	.917
	1.5550	.979	.833
	1.6500	.958	.833
	1.8400	.938	.833

	2.0150	.917	.833
	2.0650	.917	.750
	2.1300	.917	.667
	2.1650	.896	.667
	2.2000	.896	.583
	2.2350	.875	.583
	2.2550	.854	.583
	2.3400	.833	.583
	2.4250	.833	.500
	2.4600	.833	.417
	2.4950	.813	.417
	2.5550	.750	.417
	2.6300	.750	.333
	2.6850	.750	.250
	2.7500	.729	.250
	2.8700	.708	.250
	2.9900	.708	.167
	3.0400	.688	.167
	3.0750	.667	.167
	3.1300	.646	.167
	3.2350	.625	.167
	3.3700	.604	.167
	3.4450	.583	.167
	3.4850	.563	.167
	3.5350	.542	.167
	3.6600	.521	.167
	3.8000	.500	.167
	3.9050	.458	.167
	4.0250	.438	.167
	4.1150	.417	.167
	4.4500	.396	.167
	4.7550	.375	.167
	4.7800	.375	.083
	4.8400	.333	.083
	4.9200	.313	.083
	5.0300	.292	.083
	5.2450	.271	.083

	5.4350	.250	.083
	5.5550	.229	.083
	5.6400	.208	.083
	5.7450	.188	.083
	5.9800	.167	.083
	6.1450	.167	.000
	6.2100	.146	.000
	6.5250	.125	.000
	7.4950	.104	.000
	8.5850	.083	.000
	9.0800	.063	.000
	9.3950	.042	.000
	18.5550	.021	.000
	28.5000	.000	.000
TG/HDL	.6000	1.000	1.000
	1.9250	.979	1.000
	2.2850	.958	1.000
	2.3400	.938	1.000
	2.4150	.917	1.000
	2.4950	.917	.917
	2.5250	.896	.917
	2.6350	.875	.917
	2.7450	.854	.917
	2.8850	.833	.917
	3.0700	.813	.917
	3.1500	.813	.833
	3.2350	.813	.750
	3.3550	.792	.750
	3.4250	.771	.750
	3.4600	.750	.750
	3.5000	.750	.667
	3.5400	.729	.667
	3.5800	.708	.667
	3.7050	.688	.667
	3.8900	.667	.667
	3.9700	.646	.667
	4.0400	.646	.583

	4.1400	.646	.500
	4.2150	.646	.417
	4.3150	.625	.417
	4.3850	.604	.417
	4.3950	.604	.333
	4.4850	.583	.333
	4.6400	.563	.333
	4.7400	.542	.333
	4.8800	.521	.333
	5.0200	.500	.333
	5.1550	.500	.250
	5.4950	.479	.250
	5.7350	.458	.250
	5.8600	.438	.250
	6.0050	.417	.250
	6.0550	.396	.250
	6.2050	.396	.167
	6.4000	.375	.167
	6.4850	.375	.083
	6.5800	.354	.083
	6.8200	.333	.083
	7.0800	.313	.083
	7.4250	.292	.083
	7.8200	.271	.083
	8.2600	.250	.083
	8.6400	.229	.083
	8.8300	.208	.083
	9.1400	.208	.000
	9.4050	.188	.000
	9.4700	.167	.000
	9.8000	.146	.000
	10.2600	.125	.000
	10.4250	.104	.000
	11.1550	.083	.000
	14.2050	.063	.000
	18.6250	.042	.000
	23.6600	.021	.000

	27.6200	.000	.000
--	---------	------	------

The test result variable(s): APO B/APO A has at least one tie between the positive actual state group and the negative actual state group.

a. The smallest cutoff value is the minimum observed test value minus 1, and the largest cutoff value is the maximum observed test value plus 1. All the other cutoff values are the averages of two consecutive ordered observed test values.

Lampiran 5. Dokumentasi



Alat Cobas C 111



Alat Cobas C311



Lampiran 6. Riwayat Hidup (*Curriculum Vitae*)

DATA PRIBADI

Nama : Irmawati
Tempat, tanggal lahir : Ujung Pandang, 28 Januari 1998
Agama : Islam
Email : im.irmawati28@gmail.com
Pekerjaan : ATLM
Alamat : Jl. Pajjaiang No. 83

NO.	STRATA	INSTITUSI	TEMPAT	TAHUN LULUS
1	SD	SDI KELAPA TIGA 1	Makassar	2010
2	SMP	SMP Negeri 23	Makassar	2013
3	SMA	SMA Negeri 16	Makassar	2016
4.	S1	Universitas Megarezky (DIV Teknologi Laboratorium Medis)	Makassar	2020
5	S2	Ilmu Biomedik Pascasarjana Unhas	Makassar	2023